Gastric Cancer

Oncology·MeSH: Stomach Neoplasms

Prevalence

10.0 / 100K

Incidence

6.1 / 100K/yr

44 drugs in development·17 companies·76 clinical trials

Drug Pipeline by Phase

Approved(4)

Phase 3(21)

Drug	Company
apatinib	ASTRAZENECA PLC (AZN)
arx788	Ambrx Biopharma Cayman, Inc. (AMAM)
AZD0901	ASTRAZENECA PLC (AZN)
AZD4360	ASTRAZENECA PLC (AZN)
AZD5863	ASTRAZENECA PLC (AZN)
bemarituzumab	AMGEN INC (AMGN)
Chemotherapy	Merck & Co., Inc. (MRK)
Datopotamab Deruxtecan	Merus N.V. (MRUS)
Folfox Protocol	AGENUS INC (AGEN)
l-leucovorin	ASTRAZENECA PLC (AZN)
Leucovorin	ASTRAZENECA PLC (AZN)
Leucovorin	BRISTOL MYERS SQUIBB CO (BMY)
margetuximab	MACROGENICS INC (MGNX)
Margetuximab 10 mg/kg	MACROGENICS INC (MGNX)
mfolfox6	AMGEN INC (AMGN)
Rilvegostomig	ASTRAZENECA PLC (AZN)
Sonesitatug vedotin	ASTRAZENECA PLC (AZN)
sugemalimab	EQRx, Inc. (EQRX)
tas-102	ASTRAZENECA PLC (AZN)
XELOX	AGENUS INC (AGEN)
Zolbetuximab	ASTRAZENECA PLC (AZN)

Phase 2(13)

Drug	Company
Amivantamab	Structure Therapeutics Inc. (GPCR)
Amivantamab and Recombinant Human Hyaluronidase	Structure Therapeutics Inc. (GPCR)
Amivantamab IV	Structure Therapeutics Inc. (GPCR)
Amivantamab SC	Structure Therapeutics Inc. (GPCR)
AZD0901	Merus N.V. (MRUS)
bemarituzumab	TG THERAPEUTICS, INC. (TGTX)
eflornithine	PANBELA THERAPEUTICS, INC. (SNBP)
folfox	ASTRAZENECA PLC (AZN)
Ifinatamab Deruxtecan	Merus N.V. (MRUS)
infigratinib	LianBio (LIANY)
modified folfox6	TG THERAPEUTICS, INC. (TGTX)
Patritumab Deruxtecan	Merus N.V. (MRUS)
xelox	ASTRAZENECA PLC (AZN)

Phase 1(2)

Drug	Company
LB1908	Legend Biotech Corp (LEGN)
Mitomycin	IGM Biosciences, Inc. (IGMS)

Unknown(1)

Drug	Company
MyRisk	MYRIAD GENETICS INC (MYGN)

Phase 2/Phase 3(2)

Drug	Company
retifanlimab	MACROGENICS INC (MGNX)
Tebotelimab	MACROGENICS INC (MGNX)

Phase 4(1)

Drug	Company
Lapatinib	ASTRAZENECA PLC (AZN)

BioSniper tracks 44 drugs in development for Gastric Cancer across 17 companies.

There are 76 clinical trials targeting Gastric Cancer tracked by BioSniper.

The estimated prevalence of Gastric Cancer is approximately 10.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.